Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | PSMA PET-CT scan and treatments for patients with cN1 prostate cancer

Silke Gillessen, MD, PhD, of the University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the role of the PSMA PET-CT scan and its implications for prostate cancer treatment. The PSMA PET-CT scan allows identifying lymph nodes lesions with a higher sensitivity than conventional imaging methods. The presence of lymph node lesions categorizes the disease in the cN1 group. Prof. Gillessen explains that there is little consensus over how these patients should be treated. In addition, the utility of the PSMA PET-CT scan is unclear. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.